ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
CBD Life Sciences Inc (PK)

CBD Life Sciences Inc (PK) (CBDL)

0.0006
-0.0002
(-25.00%)
Closed November 04 3:00PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CBDL News

Official News Only

CBDL Discussion

View Posts
Big RDC Big RDC 19 hours ago
I think Harris is more pro on Cannabis and CBD then Trump
πŸ‘οΈ0
SmellMyFinger SmellMyFinger 1 day ago
Feel free to explain your rationale, but please, keep it on topic regarding $CBDL.
πŸ‘οΈ0
Big RDC Big RDC 2 days ago
If Harris wins we run hard if not we hit .0001 My take on it.
👍️ 1 💫 1
packerfan9 packerfan9 2 days ago
Every time they increase the A/s to billions. People argue they are not diluting. Every time wrong. Nothing has changed. Look at price after the r/s. No one had 100's of millions of shares to sell. Know who has billions to sell yet again. The company. All this is another repeat of the same thing. The revenues are so tiny. The o/s used to be over 40 billion. Nothing can justify billions sold when revenues under 200K. Even if they can ever sell millions in sales. A long way from that. They still make more selling shares. Ignore the track record and lose. Like many have thinking they would grow big revenues. CBD is a very competitive market. They will never sell enough to justify what they have done to shareholders.
πŸ‘οΈ0
koolmc koolmc 2 days ago
otcn on ask
πŸ‘οΈ0
10thMountain 10thMountain 3 days ago
Don’t know. Some people are saying they’re diluting
👍️ 1
delerious1 delerious1 3 days ago
I tried to get in this one last week and been away for a few days but I saw it rocketing...so what caused it to drop again, was it news or just the normal correction?
πŸ‘οΈ0
resx18 resx18 3 days ago
#PowerHour $CBDL
πŸ‘οΈ0
MahinAgency MahinAgency 3 days ago
$CBDL Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping Into a Booming $20 Billion Market
πŸ‘οΈ0
10thMountain 10thMountain 3 days ago
The bid is huge compared to the ask
πŸ‘οΈ0
MahinAgency MahinAgency 3 days ago
OTCMKTS: $CBDL CBD Life Sciences Inc. is entering the CBD equine market, projected to grow at 40.3% CAGR through 2028, to capture demand in this high-growth, low-competition sector.
πŸ‘οΈ0
konshe konshe 3 days ago
I don't think dilution now, O/S shares didn't increasing recently. I am ready to get in again, because business is going ahead and has good future. 0.0006 is a good buy if you can get.
πŸ‘οΈ0
 stock king 1 stock king 1 3 days ago
Imho when the real share count comes out , it might get close to 3 billion…
πŸ‘οΈ0
resx18 resx18 3 days ago
Just starting! Did you grab any 6's or 7's ? $CBDL
πŸ‘οΈ0
 stock king 1 stock king 1 3 days ago
It was a hell of a pump and dump
πŸ‘οΈ0
resx18 resx18 3 days ago
$CBDL in the loading zone !!!!!!!
πŸ‘οΈ0
10thMountain 10thMountain 3 days ago
Good morning
πŸ‘οΈ0
10thMountain 10thMountain 3 days ago
Unfortunately buyers don’t think it’s huge. Now back to .0006
πŸ‘οΈ0
konshe konshe 3 days ago
not too much sell at 0.0006?
πŸ‘οΈ0
SmellMyFinger SmellMyFinger 3 days ago
It wasn't me. As I indicated in post #85726, "Too many stocks have been lost lately after transitioning to that so-called expert market for me, personally, to endorse any of them in good faith." Ergo, I will never assist in any pumps. Let the company itself push the PPS higher organically or not at all.
πŸ‘οΈ0
resx18 resx18 3 days ago
Good Morning $CBDL
πŸ‘οΈ0
packerfan9 packerfan9 3 days ago
Smart. Only ones who ever did well here. traded in and out quickly. The ones who held all down big after dilution and r/s. Now more dilution. .
πŸ‘οΈ0
konshe konshe 3 days ago
I am sold out with profits Today I don't want my profits gone
πŸ‘οΈ0
packerfan9 packerfan9 3 days ago
Sure not here as they will sell another 4.5 billion shares. The revenues not much after years. So tiny vs billions in dilution. They will never sell enough CBD to justify it. They get rich selling shares. The traders that did well. From Nov 2020 until big increase in A/S in 2021. Been bad ever since.
πŸ‘οΈ0
packerfan9 packerfan9 3 days ago
Wrong. Just showing all the same dilution as before. I now a dilution scam when I see it. I have been right since early 2020 when they started selling billions of shares. Nothing has changed. Trading any stock timing. The problem here with massive dilution. Is nay thing else you lose. Every one holding before this r.s has a lost. I see all the same arguments now that I have for years. Rinse and repeat. I lost no money here. Sad so many fall for this scam again.
πŸ‘οΈ0
10thMountain 10thMountain 3 days ago
The big move will come on the Amazon news they said will be out soon
πŸ‘οΈ0
konshe konshe 4 days ago
down on the news What's the problem?
πŸ‘οΈ0
10thMountain 10thMountain 4 days ago
It suck’s you got caught in their r/s. Some of the biggest runs happen post r/s. I don’t know if they’ll dilute or not. But it could run again soon. Needs to fill the gaps first
πŸ‘οΈ0
packerfan9 packerfan9 4 days ago
Sure you keep thinking that. At these levels and how no one holding before r/s has a gain. After the r/s they increased a/s to 4.5 billion. The buys are filled by them. They did this before. Like you others said no increase. Wrong. Wait and see. Ignore the past here. CBD has been around for many years. Have you seen how small revenues are on the income statements? They get rich selling billions of shares over and over not CBD. Some just ignore the record here.
πŸ‘οΈ0
10thMountain 10thMountain 4 days ago
The o/s hasn’t changed
πŸ‘οΈ0
MahinAgency MahinAgency 4 days ago
CBD Life Sciences Inc. (CBDL) is poised for significant growth as federal marijuana legalization approaches, reporting a 1405% revenue increase since early 2024. The company plans to capitalize on the $70 billion cannabis market with innovative products and strategic partnerships.
πŸ‘οΈ0
packerfan9 packerfan9 4 days ago
When they increase the a/s to 4.5 billion. They will sell them all. Same as every time before they increased the a/s. The sale are tiny. They get rich selling billions of shares again again. Even at these levels. No one who owned before the last RS has a gain. It will end up to sell them all at .00001. Not the first time it has.
πŸ‘οΈ0
stealofadeal stealofadeal 4 days ago
$CBDL More fake bullsh!t news to sell Regulation A shares.
πŸ‘οΈ0
RedSox04 RedSox04 4 days ago
Bottom in here gonna bounce 
πŸ‘οΈ0
MahinAgency MahinAgency 4 days ago
CBD Life Sciences Inc. (CBDL) has launched mushroom-infused gummies targeting energy, sleep, and sexual wellness, tapping into the $20 billion mushroom market projected to grow over 14% annually. This innovative product line positions CBDL for significant growth and increased shareholder value.
πŸ‘οΈ0
konshe konshe 4 days ago
Markets positive reaction could be delayed, PPS waiting for move up.
👍️ 1
10thMountain 10thMountain 4 days ago
To investigate what?
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 4 days ago
Shareholders price prediction
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 4 days ago
0.001
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 4 days ago
Going to otc markets to investigate
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 4 days ago
Interesting sticky
πŸ‘οΈ0
TRUSTUNITS1000000 TRUSTUNITS1000000 4 days ago
Wowwww banners saw now
πŸ‘οΈ0
10thMountain 10thMountain 4 days ago
So what's the hold up with this stock? They keep pumping out news but still no movement 
πŸ‘οΈ0
Chartmaster Chartmaster 4 days ago
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping Into a Booming $20 Billion Market

Projected to reach the $20 billion global mushroom market by 2030, CBDL's entry offers shareholders a unique opportunity to capitalize on a sector growing at over 14% annually

SCOTTSDALE, AZ / ACCESSWIRE / October 31, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL) sets a new industry standard with its launch of a high-performance line of mushroom-infused gummies, designed to meet the surging demand for wellness products in a projected $20 billion market. Focused on energy, sleep, and sexual wellness, these unique formulations offer CBDL shareholders and new investors an unprecedented growth opportunity in an exploding sector.

With an expanding consumer focus on holistic health and functional ingredients, CBDL's Rise, Dream, and Bloom Gummies each bring targeted benefits, including cognitive enhancement, restful sleep, and boosted vitality. These products are strategically positioned to address top wellness priorities, blending potent natural ingredients with advanced formulation technology. This launch is expected to significantly contribute to CBDL's revenue stream, enhancing shareholder value and setting the company apart as an innovator in functional wellness.

Targeted Wellness Meets Market Demand: Three Powerful Formulations

Rise Gummies are formulated to support focus and energy, each containing 500mg of Lion's Mane Mushroom, 1 microgram of B12, and 25mg of Ginseng. This combination aligns with a growing segment of consumers seeking natural solutions to boost mental clarity and productivity.

Dream Gummies provide natural support for relaxation and sleep, with 500mg of Reishi Mushroom, 25mg of Kava, and 10mg of 5-HTP. With sleep wellness now a top priority for many, Dream Gummies offer a non-habit-forming solution to support stress relief and emotional balance.

Bloom Gummies offer a targeted formula for sexual wellness and vitality, incorporating 500mg of Cordyceps Mushroom along with Tongkat Ali, Ginkgo Biloba, Ginseng, L-Arginine, Ashwagandha, and Maca. This powerful combination is designed to support libido, energy, and overall wellness, meeting the needs of consumers prioritizing vitality and balance.

A Game-Changing Opportunity for Growth and Profitability
The global mushroom market, projected to reach $20 billion by 2030, continues to grow as consumers increasingly value natural wellness products. This trend puts CBDL in a prime position to capitalize on the expanding market, with each product tailored to high-demand wellness categories. By establishing itself early in the functional mushroom space, CBDL not only strengthens its product lineup but creates multiple revenue streams that align with future growth.

Furthermore, as CBDL advances in this sector, its market differentiation promises significant potential for profit, brand expansion, and sustained shareholder value. With early adoption into these emerging wellness sectors, CBDL is creating a scalable pathway for growth, ensuring long-term profitability and new revenue channels, particularly attractive to investors.

Why Investors Should Take Note
This new product line underscores CBDL's commitment to innovation and market leadership, poised to drive substantial revenue growth. With the functional gummy market projected to grow at over 14% annually, CBDL's unique formulations position the company as a leader in a niche that aligns perfectly with evolving consumer preferences.

For existing and potential investors, CBDL's mushroom gummy line represents an unmatched opportunity for portfolio growth. The anticipated success of Rise, Dream, and Bloom Gummies is expected to boost CBDL's market share and generate heightened interest from strategic retail partners, translating into higher returns and increased shareholder equity. With its pioneering approach to wellness, CBDL is dedicated to securing sustained value for investors by remaining at the forefront of natural health innovation.

About CBD Life Sciences, Inc.
CBD Life Sciences, Inc. (OTC PINK:CBDL) is a leading innovator in the CBD and wellness industry, committed to creating high-quality, scientifically backed products that promote health and well-being. From pain relief to overall wellness, CBD Life Sciences strives to deliver top-tier solutions that meet the needs of today's consumers.

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC

Instagram: https://www.instagram.com/cbd.vault

IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

Related Images

SOURCE: CBD Life Sciences Inc.


View the original press release on accesswire.com

© Copyright 2024 ACCESSWIRE. All Rights Reserved.
https://www.otcmarkets.com/stock/CBDL/news/story?e&id=3031198
👍️ 1
10thMountain 10thMountain 4 days ago
Nice News!
πŸ‘οΈ0
resx18 resx18 4 days ago
SCOTTSDALE, AZ / ACCESSWIRE / October 31, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL) sets a new industry standard with its launch of a high-performance line of mushroom-infused gummies, designed to meet the surging demand for wellness products in a projected $20 billion market. Focused on energy, sleep, and sexual wellness, these unique formulations offer CBDL shareholders and new investors an unprecedented growth opportunity in an exploding sector.


With an expanding consumer focus on holistic health and functional ingredients, CBDL's Rise, Dream, and Bloom Gummies each bring targeted benefits, including cognitive enhancement, restful sleep, and boosted vitality. These products are strategically positioned to address top wellness priorities, blending potent natural ingredients with advanced formulation technology. This launch is expected to significantly contribute to CBDL's revenue stream, enhancing shareholder value and setting the company apart as an innovator in functional wellness.

Targeted Wellness Meets Market Demand: Three Powerful Formulations

Rise Gummies are formulated to support focus and energy, each containing 500mg of Lion's Mane Mushroom, 1 microgram of B12, and 25mg of Ginseng. This combination aligns with a growing segment of consumers seeking natural solutions to boost mental clarity and productivity.

Dream Gummies provide natural support for relaxation and sleep, with 500mg of Reishi Mushroom, 25mg of Kava, and 10mg of 5-HTP. With sleep wellness now a top priority for many, Dream Gummies offer a non-habit-forming solution to support stress relief and emotional balance.

Bloom Gummies offer a targeted formula for sexual wellness and vitality, incorporating 500mg of Cordyceps Mushroom along with Tongkat Ali, Ginkgo Biloba, Ginseng, L-Arginine, Ashwagandha, and Maca. This powerful combination is designed to support libido, energy, and overall wellness, meeting the needs of consumers prioritizing vitality and balance.

A Game-Changing Opportunity for Growth and Profitability
The global mushroom market, projected to reach $20 billion by 2030, continues to grow as consumers increasingly value natural wellness products. This trend puts CBDL in a prime position to capitalize on the expanding market, with each product tailored to high-demand wellness categories. By establishing itself early in the functional mushroom space, CBDL not only strengthens its product lineup but creates multiple revenue streams that align with future growth.

Furthermore, as CBDL advances in this sector, its market differentiation promises significant potential for profit, brand expansion, and sustained shareholder value. With early adoption into these emerging wellness sectors, CBDL is creating a scalable pathway for growth, ensuring long-term profitability and new revenue channels, particularly attractive to investors.

Why Investors Should Take Note
This new product line underscores CBDL's commitment to innovation and market leadership, poised to drive substantial revenue growth. With the functional gummy market projected to grow at over 14% annually, CBDL's unique formulations position the company as a leader in a niche that aligns perfectly with evolving consumer preferences.

For existing and potential investors, CBDL's mushroom gummy line represents an unmatched opportunity for portfolio growth. The anticipated success of Rise, Dream, and Bloom Gummies is expected to boost CBDL's market share and generate heightened interest from strategic retail partners, translating into higher returns and increased shareholder equity. With its pioneering approach to wellness, CBDL is dedicated to securing sustained value for investors by remaining at the forefront of natural health innovation.

About CBD Life Sciences, Inc.
CBD Life Sciences, Inc. (OTC PINK:CBDL) is a leading innovator in the CBD and wellness industry, committed to creating high-quality, scientifically backed products that promote health and well-being. From pain relief to overall wellness, CBD Life Sciences strives to deliver top-tier solutions that meet the needs of today's consumers.

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC

Instagram: https://www.instagram.com/cbd.vault

IR Contact: cbdvaultaz@gmail.com
👍️ 1 💥 1
madcasper madcasper 4 days ago
who was that guy that thought he could get back in on 0009/8?
no fills here..

CBDL
πŸ‘οΈ0
peanutz peanutz 4 days ago
Like to have caught some 9's today .
πŸ‘οΈ0
packerfan9 packerfan9 5 days ago
Great if people made money off this spike. Yet look at the financials. Revenues are tiny vs making a/s 4.5 billion. Look at the track record of dilution after each time they increased it since 2021. Nothing can last when they keep diluting billions. That is why it has ended up at .00001 more than once.
πŸ‘οΈ0
konshe konshe 5 days ago
Profits taking sell happened, no triple zero stock can go up fast to penny. Charts show overbought. I sold some. to take capitaland profits.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock